These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 32622829)
1. Next-generation therapies for adrenocortical carcinoma. Altieri B; Ronchi CL; Kroiss M; Fassnacht M Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101434. PubMed ID: 32622829 [TBL] [Abstract][Full Text] [Related]
2. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884 [TBL] [Abstract][Full Text] [Related]
3. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model. Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475 [TBL] [Abstract][Full Text] [Related]
4. Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches. Chukkalore D; MacDougall K; Master V; Bilen MA; Nazha B Oncologist; 2024 Sep; 29(9):738-746. PubMed ID: 38381694 [TBL] [Abstract][Full Text] [Related]
5. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725 [TBL] [Abstract][Full Text] [Related]
6. Update on adrenocortical carcinoma management and future directions. Varghese J; Habra MA Curr Opin Endocrinol Diabetes Obes; 2017 Jun; 24(3):208-214. PubMed ID: 28277340 [TBL] [Abstract][Full Text] [Related]
7. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma. Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109 [TBL] [Abstract][Full Text] [Related]
8. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation. Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813 [TBL] [Abstract][Full Text] [Related]
9. Update in adrenocortical carcinoma. Fassnacht M; Kroiss M; Allolio B J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734 [TBL] [Abstract][Full Text] [Related]
10. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961 [TBL] [Abstract][Full Text] [Related]
17. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757 [TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907 [TBL] [Abstract][Full Text] [Related]
19. Clinical management of adrenocortical carcinoma. Fassnacht M; Allolio B Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):273-89. PubMed ID: 19500769 [TBL] [Abstract][Full Text] [Related]
20. Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art? Cremaschi V; Abate A; Cosentini D; Grisanti S; Rossini E; Laganà M; Tamburello M; Turla A; Sigala S; Berruti A Expert Opin Pharmacother; 2022 Aug; 23(12):1413-1424. PubMed ID: 35876101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]